Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 12Myelodysplastic Syndromes 5Leukemia, Myelomonocytic, Chronic 3Leukemia, Biphenotypic, Acute 2Triple Negative Breast Neoplasms 1Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Neurofibrosarcoma 1Neuroendocrine Tumors 1Neoplasms 1Myeloproliferative Disorders 1Melanoma 1Leukemia, Myeloid, Chronic-Phase 1Cytopenia 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Breast Neoplasms 1BRCA1 Mutation 1Anemia, Refractory, with Excess of Blasts 1Allogeneic Stem Cell Transplantation 1Accelerated Phase Myeloproliferative Neoplasm 1

Interventions

decitabine and cedazuridine drug combination 1Cord Blood Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Allogeneic Stem Cell Transplantation × decitabine and cedazuridine drug combination × Clear all
NCT06297629 2026-05-15

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

M.D. Anderson Cancer Center

Phase 2 Withdrawn

Allogeneic Stem Cell Transplantation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡